Yong Ben Sells 2,000 Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) Stock

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Director Yong Ben sold 2,000 shares of the stock in a transaction on Monday, September 14th. The shares were sold at an average price of $7.84, for a total value of $15,680.00. Following the sale, the director directly owned 9,383 shares in the company, valued at approximately $73,562.72. The trade was a 17.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Corbus Pharmaceuticals Stock Down 14.4%

Shares of NASDAQ:CRBP traded down $1.16 during midday trading on Tuesday, reaching $6.92. The company’s stock had a trading volume of 3,747,824 shares, compared to its average volume of 441,107. The firm has a market cap of $129.20 million, a price-to-earnings ratio of -1.12 and a beta of 2.63. The business has a 50 day moving average price of $9.75 and a 200 day moving average price of $9.45. Corbus Pharmaceuticals Holdings, Inc. has a 1 year low of $6.32 and a 1 year high of $20.56.

Corbus Pharmaceuticals (NASDAQ:CRBP) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.55). Sell-side analysts anticipate that Corbus Pharmaceuticals Holdings, Inc. will post -5.62 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Corbus Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Orbimed Advisors LLC increased its position in shares of Corbus Pharmaceuticals by 8.8% during the first quarter. Orbimed Advisors LLC now owns 1,737,287 shares of the biopharmaceutical company’s stock worth $16,313,000 after acquiring an additional 140,000 shares during the last quarter. Exome Asset Management LLC raised its position in shares of Corbus Pharmaceuticals by 67.8% in the 1st quarter. Exome Asset Management LLC now owns 234,136 shares of the biopharmaceutical company’s stock valued at $2,199,000 after purchasing an additional 94,593 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Corbus Pharmaceuticals by 76.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 136,602 shares of the biopharmaceutical company’s stock valued at $1,281,000 after purchasing an additional 59,248 shares in the last quarter. Seven Fleet Capital Management LP boosted its stake in shares of Corbus Pharmaceuticals by 51.0% during the 1st quarter. Seven Fleet Capital Management LP now owns 85,687 shares of the biopharmaceutical company’s stock valued at $805,000 after buying an additional 28,937 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Corbus Pharmaceuticals during the second quarter worth approximately $425,000. 64.64% of the stock is owned by hedge funds and other institutional investors.

Corbus Pharmaceuticals News Roundup

Here are the key news stories impacting Corbus Pharmaceuticals this week:

• Positive Sentiment: Promising CANYON-1 results: Daily oral CRB-913 produced statistically significant and clinically meaningful average weight loss of 5% at the 60-mg dose after 12 weeks, with no plateau observed. The drug was generally well tolerated, and its emerging gastrointestinal tolerability profile could help differentiate it from existing obesity therapies. Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study
• Positive Sentiment: Potential new obesity-drug class: Corbus said the findings support CRB-913’s potential as an oral, non-incretin weight-loss treatment. The data have also been selected for a late-breaking presentation at ObesityWeek 2026, increasing visibility for the program. Corbus Announces Positive Phase 1b Weight-Loss Data
• Positive Sentiment: Analyst support: HC Wainwright reaffirmed its “buy” rating and maintained a $35 price target, implying substantial upside if CRB-913 advances successfully through later-stage testing.
• Neutral Sentiment: Options activity signals heightened speculation: Traders purchased 7,228 call options Monday—about 523% above typical volume—before purchasing 10,124 put options Tuesday, roughly 690% above average. The sharp increase in both calls and puts reflects unusually high uncertainty and volatility rather than a clear consensus direction.
• Negative Sentiment: Early-stage and financial risks remain: CRB-913 has only generated Phase 1b topline data, so efficacy and safety must be confirmed in larger trials. Corbus also recently reported a wider-than-expected quarterly loss, while the stock’s decline from its 52-week high suggests investors may be taking profits or reassessing the initial enthusiasm.

Analysts Set New Price Targets

CRBP has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and set a $35.00 target price on shares of Corbus Pharmaceuticals in a report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a report on Friday, July 17th. Guggenheim reaffirmed a “buy” rating on shares of Corbus Pharmaceuticals in a research report on Tuesday, May 26th. Oppenheimer dropped their target price on Corbus Pharmaceuticals from $52.00 to $48.00 and set an “outperform” rating on the stock in a report on Friday, August 7th. Finally, Wedbush reduced their price target on Corbus Pharmaceuticals from $38.00 to $30.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 27th. Eight investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $41.00.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.